GlassScriptPhysician profile
Alexia S Covington
NPI 1841948791
$12,812.11
in general payments reported to CMS, 2019-2025
28 companies · $3,860 in 2025
The $3,860 reported for 2025 was more than what 98% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $2,077 · 2023: $4,133 · 2024: $2,742 · 2025: $3,860.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $11K · Education: $19.25.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $10,715.59 |
| Education | $19.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $5,191.20 | 2022-2025 | |
| Amgen INC. | $1,464.67 | 2022-2025 | Enbrel, Otezla, Tavneos |
| Novartis Pharmaceuticals Corporation | $1,053.00 | 2022-2025 | |
| Janssen Biotech, INC. | $837.10 | 2022-2025 | Tremfya, Simponi Aria |
| Ucb, INC. | $688.93 | 2022-2025 | Bimzelx, Cimzia |
| Astrazeneca Pharmaceuticals LP | $614.10 | 2022-2025 | Saphnelo, Wainua |
| Ani Pharmaceuticals, INC. | $355.75 | 2023-2025 | Purified Cortrophin Gel, Sovuna |
| Radius Health, INC. | $346.99 | 2022-2025 | Tymlos |
| Boehringer Ingelheim Pharmaceuticals, INC. | $306.32 | 2022-2025 | Ofev |
| Pfizer INC. | $249.39 | 2023-2025 | |
| Mallinckrodt Hospital Products INC. | $210.66 | 2024-2025 | Acthar |
| Organon LLC | $170.00 | 2023-2025 | Renflexis, Hadlima |
| Invivyd INC | $168.65 | 2025 | Pemgarda |
| Aurinia Pharma U.S., INC. | $156.32 | 2022-2025 | Lupkynis |
| Glaxosmithkline, LLC. | $148.90 | 2022-2025 | Benlysta |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $127.45 | 2022-2023 | Taltz |
| E.R. Squibb & Sons, L.L.C. | $125.93 | 2024-2025 | Orencia |
| Horizon Therapeutics Plc | $105.84 | 2022 | |
| Octapharma USA, INC. | $79.78 | 2023-2025 | Octagam Immune Globulin (Human) |
| Sandoz INC. | $70.87 | 2023-2024 | Hyrimoz |
| Sobi, INC | $59.84 | 2024-2025 | |
| Sanofi-Aventis U.S. LLC | $54.99 | 2022 | |
| Scilex Pharmaceuticals INC. | $52.42 | 2024 | |
| Genzyme Corporation | $48.84 | 2022 | |
| Fresenius Kabi USA, LLC | $44.87 | 2023-2025 | Idacio |
| Eisai INC. | $30.87 | 2025 | |
| Alexion Pharmaceuticals, INC. | $29.13 | 2022-2023 | Strensiq |
| Biotronik Nro, INC. | $19.30 | 2024 | Prospera |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alexia Covington listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.